Rev. Bras. Hematol. Hemoter. vol.30 suppl.2

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in

Within the population of CD34+ cells, a relatively low proportion (less than 1%) were negative for the surface marker CD33 or HLA-Dr, indicating a population of primitive stem

The advances in the understanding of the pathogenesis of multiple myeloma and the mechanism of drug resistance have led to the development of novel targeted therapies that are able

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.. O'Brien SG, Guilhot F,

A GITIL prospective randomized multicenter phase III study of high dose sequential chemotherapy with rituximab (R- HDS and autologous transplantation (ASCT) of peripheral blood

High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II

In this review the authors present a state of art tretment of multiple myeloma.High dose chemo-radiotherapy followed by autologous hematopoietic stem cell transplantation has been

The 5-year OS after high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients who relapsed and in patients with primary resistance were 60% and